FDA Approved Biologics for Hidradenitis Suppurativa: The 2026 Provider’s Regulatory Roadmap

Introduction: The Regulatory Landscape Has Changed

As of 2026, providers treating moderate-to-severe hidradenitis suppurativa have three FDA approved biologics for hidradenitis suppurativa at their disposal: adalimumab (Humira), secukinumab (Cosentyx), and bimekizumab (Bimzelx). Each agent carries distinct mechanisms, dosing schedules, eligibility criteria, and coverage requirements that demand careful navigation.

The pace of regulatory change has been remarkable. Bimekizumab received FDA approval in November 2024, and the March 2026 pediatric secukinumab expansion means the prescribing landscape looks meaningfully different than it did even 18 months ago. For providers, staying current is no longer optional.

HS presents a core tension in clinical practice. The disease carries a 7 to 10 year average diagnostic delay and disproportionately affects Black Americans and young women. Yet the infrastructure required to prescribe and obtain coverage for these biologics remains complex and underserved by existing guidance.

This article serves as a compliance infrastructure roadmap designed to help providers understand the regulatory, documentation, and prior authorization requirements that govern real-world biologic prescribing for HS. Matrix Biologics, a compliance-savvy partner in biologic distribution, supports providers in implementing biologic programs responsibly across all approved agents.

Understanding the Disease Burden: Why Biologic Access Matters

HS is a chronic, inflammatory skin condition affecting an estimated 0.1% to 1% of the US population, with approximately 0.9 million diagnosed prevalent cases in the United States as of 2024.

The demographic burden is significant. HS disproportionately affects women at a 4:1 female-to-male ratio. Black Americans experience a prevalence of 0.76% compared to 0.28% in White Americans. Young adults aged 18 to 25 show prevalence rates up to 1.70%.

The diagnostic delay crisis compounds these challenges. The average delay from symptom onset to diagnosis spans 7 to 10 years, with Black Americans experiencing delays up to 2 years longer. This disparity is compounded by limited dermatologic access in underserved communities.

Comorbidity burden directly influences biologic selection. Providers must consider metabolic syndrome, cardiovascular disease, inflammatory bowel disease, axial spondyloarthritis, depression (prevalence up to 30%), anxiety, and elevated suicide risk when screening patients and selecting therapies. The relationship between heart conditions and biologic therapy selection is particularly relevant when evaluating cardiovascular comorbidities in HS patients.

By the end of 2025, HS was no longer viewed as a single-drug disease state. It had become one with an emerging treatment algorithm similar to psoriasis, making provider familiarity with all three approved agents clinically essential.

The Three FDA-Approved Biologics for HS: A Regulatory Overview

All three approved biologics are indicated for moderate-to-severe HS, generally defined as a minimum combined abscess and inflammatory nodule count of 3 to 5, corresponding to Hurley Stage II or III. Notably, no head-to-head trial data exists comparing the three agents directly.

Adalimumab (Humira): The First-to-Market Standard and Its Evolving Role

Adalimumab received FDA approval for HS in September 2015 as the first biologic approved for this indication. In 2018, it received a pediatric indication for adolescents aged 12 and older.

As a TNF-α inhibitor, adalimumab offers a well-characterized mechanism with a long post-market safety record. The dosing regimen consists of 160 mg at Week 0, 80 mg at Week 2, then 40 mg weekly for maintenance.

For prescribing compliance, adalimumab is often the first biologic payers require in step therapy protocols before approving newer agents. Providers must document trial duration, response, and reason for discontinuation if switching. Multiple biosimilars are now available, affecting formulary placement and prior authorization pathways.

Secukinumab (Cosentyx): The IL-17A Inhibitor With a New Pediatric Mandate

Secukinumab received FDA approval for adult moderate-to-severe HS in October 2023. On March 13, 2026, the FDA expanded approval to include pediatric patients aged 12 years and older weighing at least 30 kg, making it the only IL-17A inhibitor approved for this population.

As a fully human monoclonal antibody targeting IL-17A, secukinumab offers a distinct mechanism for patients who have failed TNF-α inhibition. The dosing regimen includes 300 mg weekly for 5 weeks (loading phase), then every 4 weeks or every 2 weeks depending on patient response.

Providers treating adolescent HS patients must document age, weight, and Hurley staging to support prior authorization. Payer policies may lag the March 2026 label update, requiring proactive appeals with FDA approval documentation. IL-17A inhibitors may exacerbate IBD, making screening and documentation of IBD history essential before prescribing.

Bimekizumab (Bimzelx): The Dual IL-17A/F Inhibitor and the Newest Approved Option

Bimekizumab received FDA approval on November 20, 2024, based on the Phase 3 BE HEARD I and BE HEARD II trials with combined enrollment of 1,014 patients. It is the first and only approved medicine designed to selectively inhibit both IL-17A and IL-17F.

The BE HEARD EXT extension study confirmed durable benefits at two years, with reduced disease severity and improved quality of life. The dosing regimen consists of 320 mg every 2 weeks for 16 weeks (induction), then every 4 weeks for maintenance.

Currently approved for adults only, bimekizumab faces the steepest prior authorization burden. Payers may require documented failure of adalimumab and secukinumab before approval. Dual IL-17A/F inhibition is influencing biologic selection earlier in the disease course for severe or refractory cases.

Prior Authorization: The Compliance Barrier Every HS Prescriber Must Navigate

Insurance prior authorization represents one of the most significant real-world barriers to HS biologic prescribing. Incomplete documentation remains the leading cause of PA denials.

Standard payer requirements include confirmed diagnosis of moderate-to-severe HS (Hurley Stage II or III), minimum AN count of 3 to 5, documented failure of at least one conventional systemic agent for a minimum of 3 months, and board-certified dermatologist prescribing or consultation.

Providers must use recognized severity assessment tools including HiSCR (Hidradenitis Suppurativa Clinical Response), IHS4 (International Hidradenitis Suppurativa Severity Score System), and Hurley staging. Most major payers require documented adalimumab failure before approving secukinumab or bimekizumab.

A 2025 specialist survey found 48% of experts believe the required 3-month antibiotic course may risk losing the therapeutic window to prevent structural disease progression. Providers should document clinical urgency when seeking exceptions.

Building a Compliant HS Biologic Program: The Infrastructure Providers Need

Most providers possess the clinical knowledge to prescribe HS biologics but lack the operational systems to manage documentation, PA, and compliance requirements at scale.

Core components of a compliant program include standardized disease severity documentation at every relevant visit, prior treatment history tracking with dates and response assessments, PA submission workflows with payer-specific documentation packages, biologic switching protocols with documented rationale, and comorbidity screening at initiation. The growing role of the next telehealth revolution in managing chronic inflammatory conditions like HS is also reshaping how providers deliver follow-up care and monitor treatment response remotely.

Matrix Biologics offers clinical pharmacist oversight and the Integrated Safety Intelligence™ platform, providing AI-powered tools for safety profiling, regulatory pathway alignment, and real-world outcomes tracking. This infrastructure removes regulatory burden from providers, allowing focus on patient outcomes rather than administrative complexity.

Conclusion: Regulatory Complexity Is the New Clinical Competency

The HS treatment landscape continues to evolve with a pipeline that may add a fourth approved agent (sonelokimab) and a first oral option (povorcitinib) within the next 12 to 18 months.

Prescribing FDA approved biologics for hidradenitis suppurativa is no longer primarily a clinical challenge. It is a regulatory and compliance challenge requiring documentation infrastructure, PA expertise, and operational systems that most practices cannot manage alone.

Partner With Matrix Biologics to Build Your HS Biologic Compliance Program

Dermatologists, rheumatologists, primary care physicians, pharmacists, and clinic administrators seeking compliance infrastructure support for HS biologic programs can connect with Matrix Biologics. The company offers neutral, compliance-savvy guidance across all three FDA-approved HS biologics, combined with clinical pharmacist oversight and real-world outcomes tracking.

Contact Matrix Biologics at 602-480-0486 or through the website contact form at matrixbiologics.com to schedule a provider consultation. CME-accredited education programs are also available for providers seeking to deepen their understanding of HS biologic prescribing compliance.